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Bromocriptine: A Sympatholytic,
D2-Dopamine Agonist for the
Treatment of Type 2 Diabetes
B
romocriptine is a sympatholytic
D2-dopamine agonist that has been
approvedforthe treatmentoftype2
diabetes. Based on animal and human
studies, timed bromocriptine administra-
tion within 2 h of awakening is believed
to augment low hypothalamic dopamine
levels and inhibit excessive sympathetic
tone within the central nervous system
(CNS), resulting in a reduction in post-
meal plasma glucose levels due to en-
hanced suppression of hepatic glucose
production. Bromocriptine has not been
shown to augment insulin secretion or
enhance insulin sensitivity in peripheral
tissues (muscle). Addition of bromocrip-
tine to poorly controlled type 2 diabetic
patients treated with diet alone, metfor-
min, sulfonylureas, or thiazolidinediones
produces a 0.5–0.7 decrement in HbA1c.
Bromocriptine also reduces fasting and
postmeal plasma free fatty acid (FFA)
and triglyceride levels. In a 52 double-
blind, placebo-controlled study in type
2 diabetic patients, bromocriptine re-
duced the composite cardiovascular end
point by 40%. The mechanism of the
drug’sb e n e ﬁcial effect on cardiovascular
disease remains to be determined.
Introduction
Type 2 diabetes is a chronic metabolic
disordercharacterizedbyinsulinresistance,
impaired b-cell function, and multiple
other metabolic/endocrine abnormalities
(1).Becauseofitsmultifactorialpathogen-
esis, restoration of normoglycemia is difﬁ-
cult to achieve and requires multiple
antidiabetic medications that have differ-
ent mechanisms of action and can be used
in combination to produce an additive
effect (1,2). Therefore, the development
of antidiabetic agents that have novel
mechanisms of action and can be used in
combination with currently approved
medications for the treatment of type 2
diabetes is highly desirable.
Type 2 diabetic patients are at high
risk for atherosclerotic cardiovascular
complications (3). Although hyperglyce-
mia is a risk factor for coronary artery
disease and stroke, it is a relatively weak
risk factor compared with other more es-
tablished risk factors such as dyslipide-
m i a ,h y p e r t e n s i o n ,o b e s i t y ,a n dt h e
insulin resistance (metabolic) syndrome
(4,5). However, even after correction of
dyslipidemia, hypertension, and dysgly-
cemia,type2diabeticpatientsstillremain
at high risk for atherosclerotic cardiovas-
cular complications (6). Therefore, anti-
diabetic agents that not only improve
glycemia but also reduce cardiovascular
risk are desirable.
Recently, timed-release bromocrip-
tine (Cycloset), a sympatholytic dopa-
mine D2 receptor agonist, has been
approved by the U.S. Food and Drug Ad-
ministration (FDA) for the treatment of
type 2 diabetes. This centrally acting an-
tidiabetic agent has a novel mechanism of
action; reduces plasma glucose, triglycer-
ide, and FFA levels; and in a prospective
1-year study reduced cardiovascular
events. In this review, we will examine
the mechanism of action, pharmacoki-
netic properties, glucose-lowering efﬁ-
cacy, potential antiatherogenic beneﬁts,
and safety of Cycloset.
Mechanism of action
Bromocriptine is unique in that it does
not have a speciﬁc receptor that mediates
its action on glucose and lipid metabo-
lism. Rather, its effects are mediated via
resetting of dopaminergic and sympa-
thetic tone within the CNS (7). Because
the human brain is not accessible to sam-
pling, much of what we have learned
about the mechanism of action of bromo-
criptine has been derived from animal
studies.
Mammalian species living in the wild
have an incredible ability to alter their
metabolism from the insulin-sensitive/
glucose-tolerant state to the insulin-
resistant/glucose-intolerant state at exactly
the right time of the year to survive long
periods when food is sparse (rev. in 7).
During transition to the insulin-resistant
state, basal lipolytic activity increases to
spare glucose utilization by peripheral
(muscle) tissues, fat oxidation becomes
predominant, and hepatic glucose pro-
duction and gluconeogenesis rise to sup-
ply glucose to the CNS during prolonged
periods (seasons) of food deprivation. At
the end of the season, animals revert back
to their insulin-sensitive/glucose-tolerant
state. Such seasonal metabolic changes
are characteristic of all migrating birds
and hibernating animals and are governed
by changes in monoaminergic concentra-
tions/activity in the suprachiasmatic nu-
clei (SCN) of the hypothalamus—the
mammalian circadian pacemaker—and
in the ventromedial hypothalamus (VMH)
(7). These neurogenic and metabolic
changes are consistent with the thrifty
gene hypothesis (8), which proposes that
conversion to the obese, insulin-resistant
state during periods of inadequate food
supply provides a survival advantage. It
is noteworthy that development of the
insulin-resistantstateduringtheseperiods
of seasonal change precisely mimics the
type 2 diabetic state: insulin resistance
in muscle and liver, accelerated hepatic
glucose production/gluconeogenesis, hy-
perglycemia, adipocyte insulin resistance
and increased lipolysis, enhanced fat oxi-
dation, increased plasma FFA and triglyc-
eride levels, and obesity. These changes
also mimic those observed in people with
the insulin resistance syndrome (5,9).
A large body of evidence implicates
endogenous dopaminergic and seroto-
nergic rhythms in SCN and VMH in the
transition from the insulin-sensitive to
insulin-resistant state. The VMH has
multiple connections with other hypo-
thalamicnucleiandplaysapivotalrolein
modulating autonomic nervous system
function, hormonal secretion, peripheral
glucose/lipid metabolism, and feeding
behavior (10–13).
Within the VMH, multiple studies
have documented that both serotonin
and noradrenergic levels and activity are
increased during the insulin-resistant
state and decrease to normal with return
totheinsulin-sensitivestateinanimalsthat
undergo seasonal changes in metabolism
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low during the insulin-resistant state and
increase to normal following return of the
insulin-sensitivestate(20,21).Further,se-
lective destruction of dopaminergic neu-
rons in the SCN causes severe insulin
resistance(22),andanimalmodelsofnon-
seasonal obesity (i.e., ob/ob mouse [16],
Zucker fatty rat [23], high energy–fed
male Sprague-Dawley rats [24]) have re-
duceddopaminelevelsinVMHandlateral
hypothalamic nuclei. Chronic infusion of
norepinephrine and/or serotonin into the
VMH of insulin-sensitive animals causes
severe insulin resistance, glucose intoler-
ance, and accelerated lipolysisin hamsters
and rats (19,25). Conversely, systemic
(20,26,27) and intracerebral (28) bromo-
criptineadministrationininsulin-resistant
animals leads to a decrease in elevated
VMH noradrenergic and serotonergic
levels (measured in vivo by microdialysis)
with a resultant decline in hepatic glucose
production/gluconeogenesis, reduced ad-
ipose tissue lipolysis, and improved insu-
lin sensitivity. Systemic bromocriptine
also inhibits VMH responsiveness to
norepinephrine (17), and, conversely,
norepinephrine infusion into the VMH
antagonizesthebeneﬁcialeffectofbromo-
criptine on glucose tolerance and insulin
sensitivity (29). Consistent with these
observations in animals, systemic bromo-
criptine administration improves glyce-
mic control and dyslipidemia without
change in body weight in type 2 diabetic
and obese nondiabetic humans (29–31).
The proposed mechanism of action of
bromocriptine to improve glucose toler-
ance is summarized in Fig. 1.
In summary, in vertebrates circadian
rhythms of target tissue response to in-
sulin, i.e., lipolysis, hepatic glucose pro-
duction, and muscle insulin sensitivity,
are mediated via circadian rhythms within
the CNS, i.e., the SCN and VMH, and act
temporarily to regulate seasonal changes
inmetabolismandbodyfatstores/muscle
mass.
How do these circadian rhythms ap-
ply to humans and what are the impli-
cations for bromocriptine as a therapy
for type 2 diabetes since humans do not
manifest these pronounced circadian
oscillations/seasonal changes in metab-
olism? As reviewed by Cincotta and col-
leagues (7,29,32), hypothalamic centers
(SCN and VMH) that regulate these circa-
dian rhythms not only receive photic in-
puts via the optic chiasm but also receive
input from other centers throughout the
CNS, neurogenic stimuli from peripheral
tissues and gastrointestinal tract, hor-
monal signals, and signals from circulat-
ing metabolites. The net result after all of
these inputs are integrated within the hy-
pothalamus needs not to be circadian in
nature. Nonetheless, interventions, such
as bromocriptine, which alter mono-
amine neurotransmitter levels within
these hypothalamic circadian centers,
can exert signiﬁcant effects on glucose
and lipid metabolism.
Pharmacokinetics and dose
Following ingestion, Cycloset (bromo-
criptine mesylate) tablets are rapidly dis-
solved and absorbed within 30 min (29).
When ingested on an empty stomach,
the maximum plasma concentration is
reached within 60 min. Absorption is de-
layed by food and peak plasma levels are
achieved at ;120 min in the fed state.
There is extensive hepatic ﬁrst-pass extrac-
tion and metabolism, and only 5–10% of
the ingested dose reaches the systemic cir-
culation (33–35). Ninety-eight percent of
ingested bromocriptine is excreted via the
biliary route with an elimination half-life
of ;6 h. Within the liver, bromocriptine
is extensively metabolized by the cyto-
chrome P450 system, speciﬁcally CYP3A4.
There are some 20–30 metabolites, but
their biologic activity is largely unknown.
Cycloset differs from traditional bro-
mocriptine formulations, such as Parlodel,
in its quick release that provides peak
concentrations within 60 min. There is no
AB-rated equivalent for Cycloset. Cyclo-
set comes as 0.8 mg tablets. The starting
doseis0.8–1.6mg/day andcan be titrated
to a maximum of 4.6 mg/day. Cycloset is
administered as a once daily dose within
2 h of awaking. Type 2 diabetic individu-
als are believed to have an early morning
dip in dopaminergic tone, which leads to
increased sympathetic activity (25). In
vertebrate species circadian plasma pro-
lactin levels closely parallel changes in
hypothalamic levels of dopamine and in-
sulin sensitivity (rev. in 7 and 32). In lean,
normal glucose-tolerant insulin-sensitive
humans, plasma prolactin concentrations
peak at night during sleep. In contrast,
Figure 1—Proposed mechanism of action of bromocriptine to improve glucose homeostasis and
insulin sensitivity. HGP, hepatic glucose production; TG, triglyceride.
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evated (twofold) day time plasma prolac-
tin levels (29), consistent with reduced
dopaminergic tone (36). Administration
of Cycloset within 2 h of awakening re-
duces the elevated prolactin levels
(29,37,38)andisthought torestoredopa-
minergic activity, thereby reducing post-
prandial plasma glucose, triglyceride, and
FFA concentrations without increasing
plasma insulin levels (see subsequent dis-
cussion).
Mechanism of action—human trials
A number of phase 2 trials have been
performed to examine the mechanism
of action of Cycloset. In a small study of
12 nondiabetic obese hyperinsulinemic
($20 mU/mL) subjects (38), bromocrip-
tine(1.6mg/dayfor2weeks)reduced the
fasting and postprandial (standardized
meals) glucose levels without change in
body weight and with a decrease in both
fasting and postprandial plasma insulin
concentrations by ;50% (Supplementary
Fig. 1).
In a similar study, 8 weeks of timed
bromocriptine reduced day-long plasma
glucose,triglyceride,andFFAlevelswith-
out change in body weight and a small
decrease in plasma insulin concentration
in 13 nondiabetic obese women (Supple-
mentary Fig. 2) (31). Insulin-stimulated
glucose disposal,measured with theinsu-
linsuppressiontest,wasnotaltered.Since
the insulin suppression test primarily re-
ﬂects insulin-mediated glucose disposal
in muscle, the improvement in postpran-
dialplasmaglucoselevels(31)mostlikely
reﬂects enhanced suppression of hepatic
glucose production by insulin, similar to
what has been described in animals (26).
However, to date, no study has examined
hepatic glucose production following
glucose ingestion or in response to a
physiologic increase in plasma insulin
concentration in man. The decline in
postprandialplasmaFFAandtriglyceride
concentrations (32) is similar to observa-
tions in animals (26,38).
In a 16-week double-blind, placebo-
controlled study in 22 obese type 2 di-
abetic subjects treated with Cycloset for
16 weeks, HbA1c declined by 1.2%, fast-
ing plasma glucose by 54 mg/dL, and
mean plasma glucose during oral glu-
cose tolerance test by 46 mg/dL without
change in plasma insulin concentration,
bodyweight,orpercentbodyfat(30)(Sup-
plementary Fig. 3). During a two-step
euglycemic-hyperinsulinemic clamp, there
was no improvement in insulin sensitivity
during the ﬁrst, physiologic insulin clamp
step (80 mU/mL), although maximally
insulin-stimulated (377 mU/mL) glucose
disposal was increased. These results are
consistent with those observed with the
insulin suppression test (31) and demon-
strate that, within the physiologic range of
hyperinsulinemia, Cycloset does not im-
prove insulin action in muscle. During
the ﬁrst insulin clamp step, suppression
of hepatic glucose production was not
enhanced by Cycloset. However, the
steady-state plasma insulin concentration,
although physiologic for muscle, was far
above that required for half-maximal sup-
pression of hepatic glucose production,
making it difﬁcult to ascertain whether
hepatic insulin sensitivity was enhanced
by insulin.
In a provocative study (39), insulin-
treated type 2 diabetic subjects were ran-
domized to placebo (n = 11) or Cycloset
(n = 21)(4.8 mg/day) for 12 weeks. Com-
pared with placebo, Cycloset reduced
HbA1c by 0.7% and mean plasma glucose
concentration (7 A.M. to 7 P.M.)b y8 %
without change in body weight. These re-
sults are consistent with an improvement
in insulin sensitivity, although the site, i.e.,
liver versus muscle, remains to be deﬁned.
In a small (n = 17) double-blind,
placebo-controlled study (38) in nondia-
betic obese individuals with elevated di-
urnal prolactin levels (changes in plasma
prolactin parallel seasonal changes in in-
sulin sensitivity and glucose tolerance in
vertebrates [7]), Cycloset (1.6–2.4 mg/
day)plusa25%calorie-restricteddietsig-
niﬁcantly reduced body weight and body
fat content compared with placebo plus
diet.However,inalarger(n=387)placebo-
controlled 24-week study, Cycloset plus
diet failed to produce a greater weight loss
thanplaceboplusdietinobesenondiabetic
subjects(29).Ofinterest,aposthocanal-
ysis revealed that obese subjects with
elevated diurnal prolactin levels (who
represented ;1/4 of the group) lost more
weight (5.7vs. 3.0 kg) than subjects with a
normal prolactin rhythm.
Phase 3 efﬁcacy trials
Four phase 3 trials have evaluated the
efﬁcacy of Cycloset versus placebo in the
treatment of type 2 diabetic patients
(29,40,41). In all studies, Cycloset was
administered in the morning within 2 h
of awaking and individuals with atypical
day-nightworkshiftswereexcludedfrom
study. These four studies included 1) 24-
week monotherapy trial (n =1 59)(29),2)
two24-weekadd-ontosulfonylureatrials
(n = 494) (30), and 3) 52-week add-on to
various oral antidiabetic agents trial (41)
(Table 1). Results of these four studies
consistently demonstrated a placebo-
subtracted decline in HbA1c of 0.5–
0.7%. Prior to randomization and after
6 months, type 2 diabetic subjects in the
monotherapy and add-on to sulfonylurea
studies (29) were admitted to the clinical
research center for 12 h (7 A.M. to 7 P.M.)
and received standardized meals for
breakfast (0700 h), lunch (1200 h), and
dinner (1700 h). Serum glucose, insulin,
FFA,andtriglycerideconcentrationswere
measured prior to and at 1 and 2 h post-
meal ingestion. Relative to placebo, Cy-
closet signiﬁcantly reduced the fasting,
postbreakfast, postlunch, and postdinner
glucose concentrations (Supplementary
Fig. 4) without change in serum insulin
level or body weight. Cycloset also signif-
icantly reduced fasting and postmeal se-
rum FFA and triglyceride concentrations
(Supplementary Fig. 5).
In the monotherapy and add-on to
sulfonylureastudies,aprespeciﬁedanalysis
was performed on Cycloset responders
(minimumHbA1c decreasefrombaseline=
0.3%atweek8)versustheentireCycloset-
treated group (Fig. 2). In monotherapy
and add-on to sulfonylurea trials, the
decrements in HbA1c from baseline
were 20.65 and 20.63, respectively, and
responders represented 63 and 65% of
the total Cycloset-treated group (29).
The placebo-subtracted difference in
HbA1cinresponderswas1%inbothmono-
therapy and add-on to sulfonylurea trials
(Fig. 2).
Table 1—Phase 3 Cycloset efﬁcacy trials
N
Duration
(months)
Baseline
HbA1c (%)
Placebo-subtracted
change in
HbA1c (%) P
Monotherapy 159 6 8.7 20.56 ,0.02
Add-on to SU 494 6 9.4 20.55 ,0.0001
Add-on to various OHAs 3,095 12 8.3 20.6 to 20.9 ,0.01–0.001
SU, sulfonylurea.
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a large 52-week randomized, double-
blind, placebo-controlled trial in which
Cycloset was added to therapy in poorly
controlled (HbA1c .7.5%) type 2 dia-
betic patients who were taking one to
two oral hypoglycemic agents (OHAs)
(41–43). Mean baseline HbA1c was
8.3%, mean age 58 years, mean BMI 33
kg/m
2; 63% were male. In type 2 diabetic
subjects who completed 24 weeks of
treatment and who took $80% of their
medication, the placebo-subtracted de-
crease in HbA1c ranged from 0.6 to
0.9% and was consistent in subjects fail-
ing any OHA, failing metformin 6 OHA,
failingmetformin+sulfonylurea,andfail-
ing thiazolidinedione 6 OHA (Supple-
mentary Fig. 6) (41–43).
Safety and tolerability
In the Cycloset monotherapy and add-on
tosulfonylureatrials(29),sideeffectsthat
occurred more commonly in Cycloset
versus placebo were nausea (26 vs. 5%),
asthenia (15 vs. 8%), constipation (11 vs.
4%), dizziness (11 vs. 6%), and rhinitis
(8 vs. 5%). In general, these side effects
weremildandtransient.Thirteen percent
of Cycloset-treated subjects withdrew be-
causeofadverseeventscomparedwith3–
5% of placebo-treated subjects (P ,
0.01). There was no increase in serious
adverse events in the Cycloset compared
with placebo groups (2.4 vs. 4.3%, re-
spectively). There was no difference in
the incidence of hypoglycemia between
the Cycloset and placebo-treated groups
in any trial.
All-cause safety trial
Alarge (n=3,070)52-week,randomized,
placebo-controlled (2:1), double-blind
trial evaluated overall and cardiovascular
safety of Cycloset in type 2 diabetic pa-
tients treated with diet alone, one to two
OHAs, or insulin alone or with one OHA
(41). Mean age was 60 years, mean BMI
32.4kg/m
2,and mean HbA1c 8.3%.Fifty-
seven percent of subjects were male, and
ethnic background was 68% Caucasian
and 17% African American. Cycloset
therapy was initiated at 0.8 mg/day and
titrated to 4.8 mg/day, as tolerated. After
3 months, alteration in other antidiabetic
medications was permitted.
Overall, there were 8.6% serious
adverse events in the Cycloset group
and 9.6% serious adverse events in the
placebogroup(hazardratio[HR]0.89,P=
NS). Thirty-two diabetic patients (3.2%)
in the Cycloset group compared with
37 patients (1.8%) in the placebo group
experienced a prespeciﬁed cardiovascular
event (myocardial infarction, stroke,
Figure 2—Change in HbA1c in Cycloset (total
group) and placebo-treated diabetic subjects.
Cycloset responders (deﬁned as a $0.3% de-
crease in HbA1c at week 8) had a signiﬁcantly
greater decline in HbA1c (placebo-subtracted
DHbA1c = 1.0%) than the total group (ref. 29).
SU, sulfonylurea. *P , 0.01; **P , 0.001;
†P , 0.04 for Cycloset responders vs. total Cy-
closet group; ††P , 0.0001 for Cycloset re-
sponders vs. placebo.
Figure 3—Top: Kaplan-Meier plot of time to ﬁrst cardiovascular event (myocardial infarction,
stroke,hospitalizationforanginaorCHF,coronaryrevascularization,anddeath)in3,070type2
diabetic subjects treated with Cycloset or placebo for 52 weeks (ref. 41). Bottom: Kaplan-Meier
plot of time to ﬁrst cardiovascular (MACE) event (myocardial infarction, stroke, and death) in
type 2 diabetic subjects treated with Cycloset or placebo for 52 weeks (ref. 41). CVEs, cardio-
vascular events.
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for congestive heart failure [CHF], coro-
nary revascularization, and death) (HR
0.60, two-sided 95% CI 0.37–0.96, P =
0.036) (Fig. 3). Using the major adverse
cardiac events (MACE) end point (myo-
cardial infarction, stroke, and death), the
HRwasreducedintheCyclosetcompared
with placebo-treated subjects (HR 0.55,
two-sided 95% CI 0.39–0.98, P , 0.05)
(Fig. 3). Based on the composite cardiovas-
cular outcome, 79 diabetic patients need to
be treated for 1 year to avoid one cardiovas-
cular event.
Adverse events that occurred at a
frequency .5% and numerically were
greater in the Cycloset group included
nausea (32.2 vs. 7.6%), dizziness (14.8
vs. 9.2%), fatigue (13.9 vs. 6.7%), head-
ache (11.4 vs. 8.3%), vomiting (8.1 vs.
3.1%), diarrhea (8.1 vs. 8.0%), and con-
stipation (5.8 vs. 5.1%).
The mechanism(s) via which timed
bromocriptine reduces cardiovascular
events in type 2 diabetic patients remains
to be deﬁned. In the cardiovascular safety
trial (41), bromocriptine reduced HbA1c
by 0.6% (P , 0.0001), blood pressure
by 2/1 mmHg (P , 0.02), heart rate by
1b p m( P = 0.02), and plasma triglyceride
by 0.08 mmol/L (P =0 . 0 2 ) .H o w e v e r ,
these changes were modest and seem un-
likelytoexplainthe40%decreaseincom-
posite cardiovascular outcome. Although
n o tm e a s u r e di nt h es a f e t yt r i a l ,r e d u c -
tions in postprandial FFA levels have
been observed in other trials with bromo-
criptine (30,31). In animal studies, bro-
mocriptine has been shown to attenuate
theeffectofCNSsympatheticoveractivity
on the vasculature (44,45), and a direct
inhibitory effect of bromocriptine on
mitogen-stimulated proliferation of rat
vascular muscle cells and human aortic
smooth muscle cells has been demon-
strated in vitro (46). In the high fat–fed,
spontaneously hypertensive rat (SHR)—
an animal model of the insulin resistance
syndrome and eNOS uncoupling—
bromocriptine reduced pathologically el-
evated endothelial nitric oxide synthase
(eNOS) and inducible NOS (iNOS) levels
(47). Uncoupled eNOS increases NAD
[P]-H oxidase levels, resulting in genera-
tion of reactive oxygen species and de-
creased nitric oxide production, a potent
vasodilator and antiatherogenic agent. All
of these biochemical abnormalities were
reversed in the aorta of bromocriptine-
treated SHR, and aortic stiffness was
markedly reduced. Thus, a number of
biochemical/molecular abnormalities
involved in the development of athero-
sclerosis, as well as multiple circulating
cardiovascular risk factors (hyperglyce-
mia, hypertriglyceridemia, and elevated
FFA) and hypertension, improve with
bromocriptine therapy. At present, it is
unclear whether the salutatory effect of
bromocriptine to reduce cardiovascular
events (41) is related to the drug’s bene-
ﬁcial effect on any of these pathologic
processes/atherosclerotic risk factors.
Further mechanistic studies and a large,
long-term prospective study will be re-
quired to establish the mechanism of ac-
tionandcardiovascularprotectivebeneﬁt
of bromocriptine therapy.
Summary
Both as monotherapy and in combination
with other OHAs, timed bromocriptine
(Cycloset)causesa0.6–0.7%reductionin
HbA1c and reduces plasma triglyceride
and FFA concentrations in type 2 dia-
beticpatients.Ina52-weeksafetystudy,
Cycloset decreased the cardiovascular
composite end point by 40%. Other ad-
vantages of Cycloset include absence of
hypoglycemia since insulin secretion is
not stimulated, weight neutrality, no
need for dose adjustment in patients with
moderaterenalinsufﬁciency,lackofedema
and CHF, and good side effect proﬁle.
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